Advanced

Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease

Palhagen, S. E.; Dizdar, N.; Hauge, T.; Holmberg, B.; Jansson, R.; Linder, J.; Nyholm, D.; Sydow, O.; Wainwright, M. and Widner, Håkan LU , et al. (2012) In Acta Neurologica Scandinavica 126(6). p.29-33
Abstract
Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD),... (More)
Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
movement disorders, Parkinson's disease, quality of life, treatment
in
Acta Neurologica Scandinavica
volume
126
issue
6
pages
29 - 33
publisher
Wiley-Blackwell
external identifiers
  • wos:000310545400001
  • scopus:84868190961
ISSN
1600-0404
DOI
10.1111/j.1600-0404.2012.01689.x
language
English
LU publication?
yes
id
69c25a97-7e13-4953-8712-24bbf00347e2 (old id 3283349)
date added to LUP
2013-01-07 09:40:50
date last changed
2017-11-19 03:44:23
@article{69c25a97-7e13-4953-8712-24bbf00347e2,
  abstract     = {Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months.},
  author       = {Palhagen, S. E. and Dizdar, N. and Hauge, T. and Holmberg, B. and Jansson, R. and Linder, J. and Nyholm, D. and Sydow, O. and Wainwright, M. and Widner, Håkan and Johansson, A.},
  issn         = {1600-0404},
  keyword      = {movement disorders,Parkinson's disease,quality of life,treatment},
  language     = {eng},
  number       = {6},
  pages        = {29--33},
  publisher    = {Wiley-Blackwell},
  series       = {Acta Neurologica Scandinavica},
  title        = {Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease},
  url          = {http://dx.doi.org/10.1111/j.1600-0404.2012.01689.x},
  volume       = {126},
  year         = {2012},
}